The Experts below are selected from a list of 2487 Experts worldwide ranked by ideXlab platform
Enric Alvarez - One of the best experts on this subject based on the ideXlab platform.
-
improvement in subjective sleep in major depressive disorder with a novel antidepressant agomelatine randomized double blind comparison with venlafaxine
The Journal of Clinical Psychiatry, 2007Co-Authors: Patrick Lemoine, Christian Guilleminault, Enric AlvarezAbstract:Objective: Patients with major depressive disorder (MDD) experience sleep disturbances that may be worsened by some antidepressant drugs early in treatment. The aim of this study was to assess the subjective quality of sleep of patients receiving agomelatine, a new antidepressant with melatonergic MT1 and MT2 receptor agonist and 5-HT2C antagonist properties, compared with that of patients receiving venlafaxine, a serotonin-Norepinephrine Reuptake Inhibitor. Method: This double-blind, randomized study involved 332 patients with MDD (DSM-IV criteria), lasted 6 weeks, and compared the effects of agomelatine 25‐50 mg/day and venlafaxine 75‐150 mg/day, with a possible dose adjustment at 2 weeks. Subjective sleep was assessed with the Leeds Sleep Evaluation
-
improvement in subjective sleep in major depressive disorder with a novel antidepressant agomelatine randomized double blind comparison with venlafaxine
The Journal of Clinical Psychiatry, 2007Co-Authors: Patrick Lemoine, Christian Guilleminault, Enric AlvarezAbstract:Objective: Patients with major depressive disorder (MDD) experience sleep disturbances that may be worsened by some antidepressant drugs early in treatment. The aim of this study was to assess the subjective quality of sleep of patients receiving agomelatine, a new antidepressant with melatonergic MT1 and MT2 receptor agonist and 5-HT2C antagonist properties, compared with that of patients receiving venlafaxine, a serotonin-Norepinephrine Reuptake Inhibitor. Method: This double-blind, randomized study involved 332 patients with MDD (DSM-IV criteria), lasted 6 weeks, and compared the effects of agomelatine 25‐50 mg/day and venlafaxine 75‐150 mg/day, with a possible dose adjustment at 2 weeks. Subjective sleep was assessed with the Leeds Sleep Evaluation
Deron R Herr - One of the best experts on this subject based on the ideXlab platform.
-
role of prefrontal cortical calcium independent phospholipase a2 in antinociceptive effect of the Norepinephrine Reuptake Inhibitor antidepresssant maprotiline
Neuroscience, 2017Co-Authors: Weesiong Chew, Markus R. Wenk, Sukumaran Shalini, Federico Torta, Christian S Stohler, Deron R HerrAbstract:Abstract The prefrontal cortex is essential for executive functions such as decision-making and planning. There is also accumulating evidence that it is important for the modulation of pain. In this study, we investigated a possible role of prefrontal cortical calcium-independent phospholipase A 2 (iPLA 2 ) in antinociception induced by the Norepinephrine Reuptake Inhibitor (NRI) and tetracyclic (tricyclic) antidepressant, maprotiline. Intraperitoneal injections of maprotiline increased iPLA 2 mRNA and protein expression in the prefrontal cortex. This treatment also reduced grooming responses to von-Frey hair stimulation of the face after facial carrageenan injection, indicating decreased sensitivity to pain. The antinociceptive effect of maprotiline was abrogated by iPLA 2 antisense oligonucleotide injection to the prefrontal cortex, indicating a role of this enzyme in antinociception. In contrast, injection of iPLA 2 antisense oligonucleotide to the somatosensory cortex did not reduce the antinociceptive effect of maprotiline. Lipidomic analysis of the prefrontal cortex showed decrease in phosphatidylcholine species, but increase in lysophosphatidylcholine species, indicating increased PLA2 activity, and release of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) after maprotiline treatment. Differences in sphingomyelin/ceramide were also detected. These changes were not observed in maprotiline-treated mice that received iPLA 2 antisense oligonucleotide to the prefrontal cortex. Metabolites of DHA and EPA may help to strengthen a known supraspinal antinociceptive pathway from the prefrontal cortex to the periaqueductal gray. Together, results indicate a role of prefrontal cortical iPLA 2 and its enzymatic products in the antinociceptive effect of maprotiline.
-
role of prefrontal cortical calcium independent phospholipase a2 in antinociceptive effect of the Norepinephrine Reuptake Inhibitor antidepresssant maprotiline
Neuroscience, 2017Co-Authors: Weesiong Chew, Markus R. Wenk, Sukumaran Shalini, Federico Torta, Christian S Stohler, Deron R Herr, J F Yeo, Weiyi OngAbstract:The prefrontal cortex is essential for executive functions such as decision-making and planning. There is also accumulating evidence that it is important for the modulation of pain. In this study, we investigated a possible role of prefrontal cortical calcium-independent phospholipase A2 (iPLA2) in antinociception induced by the Norepinephrine Reuptake Inhibitor (NRI) and tetracyclic (tricyclic) antidepressant, maprotiline. Intraperitoneal injections of maprotiline increased iPLA2 mRNA and protein expression in the prefrontal cortex. This treatment also reduced grooming responses to von-Frey hair stimulation of the face after facial carrageenan injection, indicating decreased sensitivity to pain. The antinociceptive effect of maprotiline was abrogated by iPLA2 antisense oligonucleotide injection to the prefrontal cortex, indicating a role of this enzyme in antinociception. In contrast, injection of iPLA2 antisense oligonucleotide to the somatosensory cortex did not reduce the antinociceptive effect of maprotiline. Lipidomic analysis of the prefrontal cortex showed decrease in phosphatidylcholine species, but increase in lysophosphatidylcholine species, indicating increased PLA2 activity, and release of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) after maprotiline treatment. Differences in sphingomyelin/ceramide were also detected. These changes were not observed in maprotiline-treated mice that received iPLA2 antisense oligonucleotide to the prefrontal cortex. Metabolites of DHA and EPA may help to strengthen a known supraspinal antinociceptive pathway from the prefrontal cortex to the periaqueductal gray. Together, results indicate a role of prefrontal cortical iPLA2 and its enzymatic products in the antinociceptive effect of maprotiline.
Weesiong Chew - One of the best experts on this subject based on the ideXlab platform.
-
role of prefrontal cortical calcium independent phospholipase a2 in antinociceptive effect of the Norepinephrine Reuptake Inhibitor antidepresssant maprotiline
Neuroscience, 2017Co-Authors: Weesiong Chew, Markus R. Wenk, Sukumaran Shalini, Federico Torta, Christian S Stohler, Deron R HerrAbstract:Abstract The prefrontal cortex is essential for executive functions such as decision-making and planning. There is also accumulating evidence that it is important for the modulation of pain. In this study, we investigated a possible role of prefrontal cortical calcium-independent phospholipase A 2 (iPLA 2 ) in antinociception induced by the Norepinephrine Reuptake Inhibitor (NRI) and tetracyclic (tricyclic) antidepressant, maprotiline. Intraperitoneal injections of maprotiline increased iPLA 2 mRNA and protein expression in the prefrontal cortex. This treatment also reduced grooming responses to von-Frey hair stimulation of the face after facial carrageenan injection, indicating decreased sensitivity to pain. The antinociceptive effect of maprotiline was abrogated by iPLA 2 antisense oligonucleotide injection to the prefrontal cortex, indicating a role of this enzyme in antinociception. In contrast, injection of iPLA 2 antisense oligonucleotide to the somatosensory cortex did not reduce the antinociceptive effect of maprotiline. Lipidomic analysis of the prefrontal cortex showed decrease in phosphatidylcholine species, but increase in lysophosphatidylcholine species, indicating increased PLA2 activity, and release of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) after maprotiline treatment. Differences in sphingomyelin/ceramide were also detected. These changes were not observed in maprotiline-treated mice that received iPLA 2 antisense oligonucleotide to the prefrontal cortex. Metabolites of DHA and EPA may help to strengthen a known supraspinal antinociceptive pathway from the prefrontal cortex to the periaqueductal gray. Together, results indicate a role of prefrontal cortical iPLA 2 and its enzymatic products in the antinociceptive effect of maprotiline.
-
role of prefrontal cortical calcium independent phospholipase a2 in antinociceptive effect of the Norepinephrine Reuptake Inhibitor antidepresssant maprotiline
Neuroscience, 2017Co-Authors: Weesiong Chew, Markus R. Wenk, Sukumaran Shalini, Federico Torta, Christian S Stohler, Deron R Herr, J F Yeo, Weiyi OngAbstract:The prefrontal cortex is essential for executive functions such as decision-making and planning. There is also accumulating evidence that it is important for the modulation of pain. In this study, we investigated a possible role of prefrontal cortical calcium-independent phospholipase A2 (iPLA2) in antinociception induced by the Norepinephrine Reuptake Inhibitor (NRI) and tetracyclic (tricyclic) antidepressant, maprotiline. Intraperitoneal injections of maprotiline increased iPLA2 mRNA and protein expression in the prefrontal cortex. This treatment also reduced grooming responses to von-Frey hair stimulation of the face after facial carrageenan injection, indicating decreased sensitivity to pain. The antinociceptive effect of maprotiline was abrogated by iPLA2 antisense oligonucleotide injection to the prefrontal cortex, indicating a role of this enzyme in antinociception. In contrast, injection of iPLA2 antisense oligonucleotide to the somatosensory cortex did not reduce the antinociceptive effect of maprotiline. Lipidomic analysis of the prefrontal cortex showed decrease in phosphatidylcholine species, but increase in lysophosphatidylcholine species, indicating increased PLA2 activity, and release of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) after maprotiline treatment. Differences in sphingomyelin/ceramide were also detected. These changes were not observed in maprotiline-treated mice that received iPLA2 antisense oligonucleotide to the prefrontal cortex. Metabolites of DHA and EPA may help to strengthen a known supraspinal antinociceptive pathway from the prefrontal cortex to the periaqueductal gray. Together, results indicate a role of prefrontal cortical iPLA2 and its enzymatic products in the antinociceptive effect of maprotiline.
Lawrence P. Carter - One of the best experts on this subject based on the ideXlab platform.
-
a randomized study of solriamfetol for excessive sleepiness in narcolepsy
Annals of Neurology, 2019Co-Authors: Michael J Thorpy, Lawrence P. Carter, Colin M Shapiro, Geert Mayer, Bruce C Corser, Helene A Emsellem, Giuseppe Plazzi, D Chen, Hao Wang, Jed BlackAbstract:Objective Solriamfetol (JZP‐110) is a selective dopamine and Norepinephrine Reuptake Inhibitor with wake‐promoting effects. This phase 3 study ({"type":"clinical-trial","attrs":{"text":"NCT02348593","term_id":"NCT02348593"}}NCT02348593) evaluated the safety and efficacy of solriamfetol in narcolepsy.
-
A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and Norepinephrine Reuptake Inhibitor.
Journal of psychopharmacology (Oxford England), 2018Co-Authors: Lawrence P. Carter, Jack E. Henningfield, Y. Grace Wang, Debra Kelsh, Bradley Vince, Edward M. SellersAbstract:Background:This study evaluated the human abuse potential of solriamfetol (formerly JZP-110), a selective dopamine and Norepinephrine Reuptake Inhibitor with robust wake-promoting effects.Methods:A...
-
characterization of the neurochemical and behavioral effects of solriamfetol jzp 110 a selective dopamine and Norepinephrine Reuptake Inhibitor
Journal of Pharmacology and Experimental Therapeutics, 2018Co-Authors: Michelle G Baladi, Lawrence P. Carter, Michael J Forster, Michael B Gatch, Richard B Mailman, Danielle L Hyman, Aaron JanowskyAbstract:Excessive sleepiness (ES) is associated with several sleep disorders, including narcolepsy and obstructive sleep apnea (OSA). A role for monoaminergic systems in treating these conditions is highlighted by the clinical use of US Food and Drug Administration-approved drugs that act on these systems, such as dextroamphetamine, methylphenidate, modafinil, and armodafinil. Solriamfetol (JZP-110) is a wake-promoting agent that is currently being evaluated to treat ES in patients with narcolepsy or OSA. Clinical and preclinical data suggest that the wake-promoting effects of solriamfetol differ from medications such as modafinil and amphetamine. The goal of the current studies was to characterize the mechanism of action of solriamfetol at monoamine transporters using in vitro and in vivo assays. Results indicate that solriamfetol has dual Reuptake inhibition activity at dopamine (DA; IC50 = 2.9 μM) and Norepinephrine (NE; IC50 = 4.4 μM) transporters, and this activity is associated in vivo with increased extracellular concentration of DA and NE as measured by microdialysis. Solriamfetol has negligible functional activity at the serotonin transporter (IC50 > 100 μM). Moreover, the wake-promoting effects of solriamfetol are probably owing to activity at DA and NE transporters rather than other neurotransmitter systems, such as histamine or orexin. The dual activity of solriamfetol at DA and NE transporters and the lack of significant monoamine-releasing properties of solriamfetol might explain the differences in the in vivo effects of solriamfetol compared with modafinil or amphetamine. Taken together, these data suggest that solriamfetol may offer an important advancement in the treatment of ES in patients with narcolepsy or OSA.
-
suppl._mat – Supplemental material for A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and Norepinephrine Reuptake Inhibitor
2018Co-Authors: Lawrence P. Carter, Jack E. Henningfield, Debra Kelsh, Bradley Vince, Grace Y Wang, Edward SellersAbstract:Supplemental material, suppl._mat for A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and Norepinephrine Reuptake Inhibitor by Lawrence P Carter, Jack E Henningfield, Y Grace Wang, Yuan Lu, Debra Kelsh, Bradley Vince and Edward Sellers in Journal of Psychopharmacology
Patrick Lemoine - One of the best experts on this subject based on the ideXlab platform.
-
improvement in subjective sleep in major depressive disorder with a novel antidepressant agomelatine randomized double blind comparison with venlafaxine
The Journal of Clinical Psychiatry, 2007Co-Authors: Patrick Lemoine, Christian Guilleminault, Enric AlvarezAbstract:Objective: Patients with major depressive disorder (MDD) experience sleep disturbances that may be worsened by some antidepressant drugs early in treatment. The aim of this study was to assess the subjective quality of sleep of patients receiving agomelatine, a new antidepressant with melatonergic MT1 and MT2 receptor agonist and 5-HT2C antagonist properties, compared with that of patients receiving venlafaxine, a serotonin-Norepinephrine Reuptake Inhibitor. Method: This double-blind, randomized study involved 332 patients with MDD (DSM-IV criteria), lasted 6 weeks, and compared the effects of agomelatine 25‐50 mg/day and venlafaxine 75‐150 mg/day, with a possible dose adjustment at 2 weeks. Subjective sleep was assessed with the Leeds Sleep Evaluation
-
improvement in subjective sleep in major depressive disorder with a novel antidepressant agomelatine randomized double blind comparison with venlafaxine
The Journal of Clinical Psychiatry, 2007Co-Authors: Patrick Lemoine, Christian Guilleminault, Enric AlvarezAbstract:Objective: Patients with major depressive disorder (MDD) experience sleep disturbances that may be worsened by some antidepressant drugs early in treatment. The aim of this study was to assess the subjective quality of sleep of patients receiving agomelatine, a new antidepressant with melatonergic MT1 and MT2 receptor agonist and 5-HT2C antagonist properties, compared with that of patients receiving venlafaxine, a serotonin-Norepinephrine Reuptake Inhibitor. Method: This double-blind, randomized study involved 332 patients with MDD (DSM-IV criteria), lasted 6 weeks, and compared the effects of agomelatine 25‐50 mg/day and venlafaxine 75‐150 mg/day, with a possible dose adjustment at 2 weeks. Subjective sleep was assessed with the Leeds Sleep Evaluation
